262 related articles for article (PubMed ID: 10792343)
1. Growth hormone and prolactin are secreted more irregularly in patients with Cushing's disease.
Veldman RG; Frölich M; Pincus SM; Veldhuis JD; Roelfsema F
Clin Endocrinol (Oxf); 2000 May; 52(5):625-32. PubMed ID: 10792343
[TBL] [Abstract][Full Text] [Related]
2. Apparently complete restoration of normal daily adrenocorticotropin, cortisol, growth hormone, and prolactin secretory dynamics in adults with Cushing's disease after clinically successful transsphenoidal adenomectomy.
Veldman RG; Frölich M; Pincus SM; Veldhuis JD; Roelfsema F
J Clin Endocrinol Metab; 2000 Nov; 85(11):4039-46. PubMed ID: 11095430
[TBL] [Abstract][Full Text] [Related]
3. Growth hormone and prolactin responses to corticotrophin-releasing-hormone in patients with Cushing's disease: a paracrine action of the adenomatous corticotrophic cells?
Loli P; Boccardi E; Branca V; Bramerio M; Barberis M; Losa M; Terreni MT; Lodrini S; Pollo B; Vignati F
Clin Endocrinol (Oxf); 1998 Oct; 49(4):433-9. PubMed ID: 9876339
[TBL] [Abstract][Full Text] [Related]
4. Acquired prolactin deficiency (APD) after treatment for Cushing's disease is a reliable marker of irreversible severe GHD but does not reflect disease status.
Mukherjee A; Murray RD; Teasdale GM; Shalet SM
Clin Endocrinol (Oxf); 2004 Apr; 60(4):476-83. PubMed ID: 15049963
[TBL] [Abstract][Full Text] [Related]
5. Increased episodic release and disorderliness of prolactin secretion in both micro- and macroprolactinomas.
Groote Veldman R; van den Berg G; Pincus SM; Frölich M; Veldhuis JD; Roelfsema F
Eur J Endocrinol; 1999 Mar; 140(3):192-200. PubMed ID: 10216513
[TBL] [Abstract][Full Text] [Related]
6. Growth hormone secretion in primary adrenal Cushing's syndrome is disorderly and inversely correlated with body mass index.
van Aken MO; Pereira AM; Frölich M; Romijn JA; Pijl H; Veldhuis JD; Roelfsema F
Am J Physiol Endocrinol Metab; 2005 Jan; 288(1):E63-70. PubMed ID: 15328071
[TBL] [Abstract][Full Text] [Related]
7. Profound amplification of secretory-burst mass and anomalous regularity of ACTH secretory process in patients with Nelson's syndrome compared with Cushing's disease.
van Aken MO; Pereira AM; van den Berg G; Romijn JA; Veldhuis JD; Roelfsema F
Clin Endocrinol (Oxf); 2004 Jun; 60(6):765-72. PubMed ID: 15163342
[TBL] [Abstract][Full Text] [Related]
8. Biochemical assessment of Cushing's disease in patients with corticotroph macroadenomas.
Katznelson L; Bogan JS; Trob JR; Schoenfeld DA; Hedley-Whyte ET; Hsu DW; Zervas NT; Swearingen B; Sleeper M; Klibanski A
J Clin Endocrinol Metab; 1998 May; 83(5):1619-23. PubMed ID: 9589666
[TBL] [Abstract][Full Text] [Related]
9. High prolactin levels in patients with Cushing's disease without pathological evidence of pituitary adenoma.
Comtois R; Beauregard H; Hardy J; Robert F; Somma M
Clin Endocrinol (Oxf); 1993 Jun; 38(6):601-7. PubMed ID: 8392915
[TBL] [Abstract][Full Text] [Related]
10. Ghrelin is no longer able to stimulate growth hormone secretion in patients with Cushing's syndrome but instead induces exaggerated corticotropin and cortisol responses.
Leal-Cerro A; Torres E; Soto A; Dios E; Deghenghi R; Arvat E; Ghigo E; Dieguez C; Casanueva FF
Neuroendocrinology; 2002 Dec; 76(6):390-6. PubMed ID: 12566947
[TBL] [Abstract][Full Text] [Related]
11. Effects of alprazolam, a benzodiazepine, on the ACTH-, GH- and PRL-releasing activity of hexarelin, a synthetic peptidyl GH secretagogue (GHS), in patients with simple obesity and in patients with Cushing's disease.
Grottoli S; Arvat E; Gauna C; Maccagno B; Ramunni J; Giordano R; Maccario M; Deghenghi R; Ghigo E
Pituitary; 1999 Nov; 2(3):197-204. PubMed ID: 11081154
[TBL] [Abstract][Full Text] [Related]
12. Effects of a met-enkephalin analog on adrenocorticotropin (ACTH), growth hormone, and prolactin in patients with ACTH hypersecretion.
Allolio B; Winkelmann W; Hipp FX; Kaulen D; Mies R
J Clin Endocrinol Metab; 1982 Jul; 55(1):1-7. PubMed ID: 6281297
[TBL] [Abstract][Full Text] [Related]
13. Enhanced growth hormone (GH) responsiveness to GH-releasing hormone after dietary restriction in patients with Cushing's syndrome.
Leal-Cerro A; Venegas E; Garcia-Pesquera F; Jimenez LM; Astorga R; Casanueva FF; Dieguez C
Clin Endocrinol (Oxf); 1998 Jan; 48(1):117-21. PubMed ID: 9509077
[TBL] [Abstract][Full Text] [Related]
14. Hyperleptinemia in women with Cushing's disease is driven by high-amplitude pulsatile, but orderly and eurhythmic, leptin secretion.
Veldman RG; Frölich M; Pincus SM; Veldhuis JD; Roelfsema F
Eur J Endocrinol; 2001 Jan; 144(1):21-7. PubMed ID: 11174833
[TBL] [Abstract][Full Text] [Related]
15. Effect of withdrawal of somatostatin plus growth hormone (GH)-releasing hormone as a stimulus of GH secretion in Cushing's syndrome.
Leal-Cerro A; Soto A; Martínez MA; Alvarez P; Isidro L; Casanueva FF; Dieguez C; Cordido F
Clin Endocrinol (Oxf); 2002 Dec; 57(6):745-9. PubMed ID: 12460324
[TBL] [Abstract][Full Text] [Related]
16. Selective bilateral and simultaneous catheterization of the inferior petrosal sinus: CRF stimulates prolactin secretion from ACTH-producing microadenomas in Cushing's disease.
Schulte HM; Allolio B; Günther RW; Benker G; Winkelmann W; Ohnhaus EE; Reinwein D
Clin Endocrinol (Oxf); 1988 Mar; 28(3):289-95. PubMed ID: 2844450
[TBL] [Abstract][Full Text] [Related]
17. Cyclic Cushing's disease in association with a pituitary stone.
La Civita KA; McDonald S; Jacobson J
South Med J; 1989 Sep; 82(9):1174-6. PubMed ID: 2549643
[TBL] [Abstract][Full Text] [Related]
18. Impact of two or three daily subcutaneous injections of hexarelin, a synthetic growth hormone (GH) secretagogue, on 24-h GH, prolactin, adrenocorticotropin and cortisol secretion in humans.
Maccario M; Veldhuis JD; Broglio F; Vito LD; Arvat E; Deghenghi R; Ghigo E
Eur J Endocrinol; 2002 Mar; 146(3):310-8. PubMed ID: 11888836
[TBL] [Abstract][Full Text] [Related]
19. Adrenocorticotropin and cortisol hyperresponsiveness to hexarelin in patients with Cushing's disease bearing a pituitary microadenoma, but not in those with macroadenoma.
Arvat E; Giordano R; Ramunni J; Arnaldi G; Colao A; Deghenghi R; Lombardi G; Mantero F; Camanni F; Ghigo E
J Clin Endocrinol Metab; 1998 Dec; 83(12):4207-11. PubMed ID: 9851753
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of growth hormone release after the combined administration of GHRH and GHRP-6 in patients with Cushing's syndrome.
Leal-Cerro A; Pumar A; Garcia-Garcia E; Dieguez C; Casanueva FF
Clin Endocrinol (Oxf); 1994 Nov; 41(5):649-54. PubMed ID: 7828354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
